Brno

• A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS) Ended recruitment
  2023-506827-26-00 5 2019-05-02 While it is well-established that long-term good glycaemic control wil
• A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd … Ended recruitment
  2024-511781-37-00 4 2019-04-16 YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIG
• This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre … Ended recruitment
  2023-509349-11-00 5 2019-03-22 Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll … Ended recruitment
  2023-509602-29-00 5 2019-02-11 Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended recruitment
  2023-506125-10-00 5 2018-12-24 Multiple Myeloma
• A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subject … Ended recruitment
  2023-506112-40-00 5 2018-09-26 R/R Multiple Myeloma
• A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt … Ended recruitment
  2023-509976-40-00 5 2018-05-28 Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First- … Ended recruitment
  2023-503469-49-00 5 2018-04-19 Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
• A study to investigate the clinical benefit of isatuximab in combination with bortezomib, lenalidomide and dexamethasone in adults with newl … Ended recruitment
  2024-514417-34-00 5 2017-12-14 Cancer
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination wi … Ended recruitment
  2023-509354-58-00 5 2017-07-14 Mantle Cell Lymphoma
• Study to Evaluate Imetelstat (GRN163L) in Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Ended recruitment
  2024-511348-25-00 10 2015-12-11 Myelodysplastic syndromes (MDS)
• Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study Halted
  2024-518951-52-00 4 2025-11-12 Worsening Heart Failure
• Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection Ended
  2024-519856-94-00 4 2025-08-18 Cystic fibrosis
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509197-35-00 5 2024-10-17 Thyroid Eye Disease (TED)
• Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in … Ended
  2022-502095-23-01 10 2024-09-10 Primary Immunodeficiency Diseases
• A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec … Ended
  2023-508736-62-00 4 2024-08-08 Heart failure (HF) with reduced ejection fraction (HFrEF)
• A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti … Ended
  2023-508737-13-00 4 2024-08-08 chronic heart failure
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 Idiopathic pulmonary fibrosis (IPF)
• A Phase IIb Two-Cohort, Randomised, Placebo controlled, Double blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Ch … Ended
  2023-510148-19-00 4 2024-07-03 Chronic Heart Failure
• An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budig … Ended
  2023-508356-19-00 4 2024-06-25 Pancreatic adenocarcinoma metastatic
• Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR Ended
  2023-507667-19-00 3 2024-06-06 Polymyalgia rheumatica (PMR)
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended
  2023-503693-20-01 5 2024-04-10 Severe eosinophilic asthma

Showing 265–288 of 353 trials